Intercept Pharmaceuticals (ICPT) Stock Price Up 3.5%

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) shares rose 3.5% during trading on Friday . The company traded as high as $72.40 and last traded at $73.21. Approximately 602,691 shares traded hands during trading, a decline of 33% from the average daily volume of 901,997 shares. The stock had previously closed at $70.76.

ICPT has been the subject of a number of research reports. ValuEngine upgraded Intercept Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday. Zacks Investment Research downgraded Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Wells Fargo reiterated a “market perform” rating and set a $57.00 target price (down from $62.00) on shares of Intercept Pharmaceuticals in a research report on Tuesday, February 13th. Oppenheimer reiterated a “hold” rating on shares of Intercept Pharmaceuticals in a research report on Monday, January 29th. Finally, Cantor Fitzgerald set a $58.00 target price on Intercept Pharmaceuticals and gave the company a “hold” rating in a research report on Wednesday, February 14th. Four investment analysts have rated the stock with a sell rating, ten have given a hold rating and ten have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $128.75.

How to Become a New Pot Stock Millionaire

The firm has a market cap of $1,620.11, a price-to-earnings ratio of -4.96 and a beta of -1.82. The company has a quick ratio of 4.31, a current ratio of 4.31 and a debt-to-equity ratio of 21.71.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($4.43) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.39) by ($1.04). Intercept Pharmaceuticals had a negative net margin of 275.18% and a negative return on equity of 267.95%. The company had revenue of $37.69 million for the quarter, compared to analysts’ expectations of $39.01 million. During the same quarter in the previous year, the company posted ($4.84) EPS. The business’s quarterly revenue was up 173.1% on a year-over-year basis. analysts forecast that Intercept Pharmaceuticals Inc will post -12.6 earnings per share for the current year.

Large investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc raised its holdings in Intercept Pharmaceuticals by 48.2% during the 3rd quarter. Legal & General Group Plc now owns 8,856 shares of the biopharmaceutical company’s stock valued at $514,000 after buying an additional 2,882 shares during the period. Peregrine Capital Management LLC purchased a new stake in Intercept Pharmaceuticals in the fourth quarter worth $7,055,000. Hudson Bay Capital Management LP purchased a new stake in Intercept Pharmaceuticals in the fourth quarter worth $1,753,000. State of Wisconsin Investment Board increased its stake in Intercept Pharmaceuticals by 221.0% in the fourth quarter. State of Wisconsin Investment Board now owns 11,689 shares of the biopharmaceutical company’s stock worth $683,000 after purchasing an additional 8,047 shares during the period. Finally, Spark Investment Management LLC increased its stake in Intercept Pharmaceuticals by 43.9% in the fourth quarter. Spark Investment Management LLC now owns 181,110 shares of the biopharmaceutical company’s stock worth $10,580,000 after purchasing an additional 55,210 shares during the period. Institutional investors own 74.27% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was reported by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3335771/intercept-pharmaceuticals-icpt-stock-price-up-3-5.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Mobile Mini  & Global Power Equipment Gr  Critical Review
Mobile Mini & Global Power Equipment Gr Critical Review
Ipsen  and Its Peers Critical Review
Ipsen and Its Peers Critical Review
Bloomin’ Brands  Receives $22.63 Consensus Price Target from Analysts
Bloomin’ Brands Receives $22.63 Consensus Price Target from Analysts
Analysts Set Hyatt  Target Price at $80.08
Analysts Set Hyatt Target Price at $80.08
Brokerages Anticipate American Vanguard Co.  to Post $0.14 Earnings Per Share
Brokerages Anticipate American Vanguard Co. to Post $0.14 Earnings Per Share
Badger Daylighting Ltd  Plans Dividend Increase – $0.05 Per Share
Badger Daylighting Ltd Plans Dividend Increase – $0.05 Per Share


© 2006-2018 Ticker Report. Google+.